Information for Recently Diagnosed Patients and their Loved Ones
The diagnosis of an ophthalmic disease can be alarming. However, if you or a loved one has been diagnosed with an ocular disease, learning more and connecting with appropriate organizations and support groups are helpful ways to be better informed, manage the condition, and gain support.
Below are some steps to take for the patient’s journey:
Research your disease
reVision’s website provides a brief overview of diseases relating to our pipeline. We encourage you to conduct your own research on reputable organization websites and peer-reviewed journal publications.
Find a specialist
In ophthalmology, there are specialists who see and study a specific subset of patients regularly. These specialists are better able to address complications, discuss your diagnosis, conduct tests and exams, and recommend clinical trials and therapies. The following link may provide some helpful content in looking for specialists.
Foundation Fighting Blindness provides a list of retinal specialists across the United States.
Evaluate if genetic testing is right for you and your diagnosis
Research has shown there are over 350 genes associated with retinal degenerative diseases. If applicable genetic tests can:
Provide additional evidence for diagnosis
Provide more information about the inheritance pattern, or risk of inheriting the condition
Clinical trials: some clinical trials require a genetic diagnosis to be a part of the study
Get connected with patient support groups
Being a part of patient support or advocacy groups is a great way to connect with other individuals and families who have a shared experience with ophthalmic disorders. These groups can also provide information about the latest research, resources, and other helpful advice.
Disclaimer: These link(s) are provided for your convenience. reVision Therapeutics, Inc. does not endorse the content of external websites. The content of these websites is not under the control, responsibility, or liability of reVision Therapeutics, Inc.